Astellas Pharma's VEOZAH shows significant improvements in sleep quality and menopause symptoms in new real-world study data, bolstering the drug's commercial outlook.
Astellas Pharma's VEOZAH (fezolinetant) has demonstrated statistically significant improvements in both vasomotor symptoms (VMS) and objective sleep quality in real-world data. These findings, consistent across weeks 4, 8, and 12, strengthen the clinical value proposition of the drug, likely enhancing its market adoption and commercial trajectory for menopause symptom management.
The data confirms that fezolinetant provides statistically significant improvements in both bothersome vasomotor symptoms and objective sleep quality.
Improvements were observed as early as week 4 and sustained through weeks 8 and 12.
Astellas Pharma announced statistically significant improvements in sleep quality and vasomotor symptoms for patients using VEOZAH. The real-world data, tracked over 12 weeks, reinforces the clinical efficacy of the menopause treatment.
The data confirms that VEOZAH provides statistically significant relief for menopause-related vasomotor symptoms and improves sleep quality in real-world settings.